Eli Lilly and Company

Sr Advisor / Scientific Director - Chemistry – Fragment Hit Elaboration

San Diego, California, United States

$150,000 – $225,000Compensation
Senior (5 to 8 years), Mid-level (3 to 4 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Drug DiscoveryIndustries

Requirements

Candidates should possess a Ph.D. in Chemistry or a related discipline, along with a minimum of 8 years of experience in medicinal chemistry, particularly in fragment-based drug discovery, and demonstrated expertise in developing fragment hits into pre-lead candidates. Strong knowledge of chemical synthesis, structure-activity relationships, and molecular design principles is essential.

Responsibilities

The Sr Advisor / Scientific Director will lead strategy and execution for early-stage medicinal chemistry, transforming fragment hits into pre-lead candidates through triage, insight extraction, and coordination with internal and external chemistry resources. They will collaborate with multidisciplinary teams including chemistry, biophysics, structural biology, and AI/ML to advance the FBLD platform and deliver chemical matter in a timely manner.

Skills

Chemical Synthesis
Structure-Activity Relationships
Molecular Design
Fragment-Based Drug Discovery
Medicinal Chemistry
Chemical Biology

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Key Metrics

Indianapolis, IndianaHeadquarters
1876Year Founded
$1,180.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.
Potential construction delays in Indiana could affect GLP-1 drug production timelines.
Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.
Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.
FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.
Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.
Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI